血尿酸与首次急性缺血性脑卒中患者TOAST分型及预后的相关性

doi:10.3969/j.issn.1004-583X.2024.03.003

临床荟萃 ›› 2024, Vol. 39 ›› Issue (3): 216-221.doi: 10.3969/j.issn.1004-583X.2024.03.003

血尿酸与首次急性缺血性脑卒中患者TOAST分型及预后的相关性

宋梦姣^1a, 王睿琪^1a, 曹灿², 程光森^1b, 刘羽^1b, 李忠亮^1b, 杨建豪^1b()

1.珠海市人民医院(暨南大学珠海临床医学院) a.药学部;b.脑血管病科,广东珠海 519000
2.珠海市金湾区平沙社区卫生服务中心,广东珠海 519000

收稿日期:2023-12-15 出版日期:2024-03-20 发布日期:2024-06-12
通讯作者: 杨建豪 E-mail:670166791@qq.com
基金资助:
国家自然科学基金(青年科学基金项目)——肝癌中钙调磷酸酶RCAN2/FGFR4调节免疫浸润逆转仑伐替尼治疗耐药的机制研究(82303902);2023年PSM广东药学科普研究基金(先声基金)项目——探索新媒体模式在脑卒中患者用药科普中的应用(2023KP54);珠海市科技计划医疗卫生项目(一般项目)——药学服务在缺血性脑卒中患者二级预防中的作用评价及其管理模式的研究(ZH2202200042HJL);珠海市医学科研基金项目——丁苯酞对颈动脉支架置入术患者围手术期并发症的影响(ZH24013310210073PWC)

Correlation between serum uric acid with TOAST classification and prognosis in patients with first-onset acute ischemic stroke

Song Mengjiao^1a, Wang Ruiqi^1a, Cao Can², Cheng Guangsen^1b, Liu Yu^1b, Li Zhongliang^1b, Yang Jianhao^1b()

1a. Department of Pharmacy; b. Department of Cerebrovascular Disease, Zhuhai People’s Hospital (Zhuhai Clinical Medical College of Jinan University), Zhuhai 519000, China
2. Zhuhai Jinwan District Pingsha Community Health Service Center, Zhuhai 519000, China

Received:2023-12-15 Online:2024-03-20 Published:2024-06-12
Contact: Yang Jianhao E-mail:670166791@qq.com

摘要/Abstract

摘要：

目的探究血尿酸与首次急性缺血性脑卒中患者类肝素药物治疗急性缺血性脑卒中试验(trial of org 10172 in acute stroke treatment,TOAST)分型和长期预后的相关性。方法选取2020年10月至2021年10月于珠海市人民医院住院治疗的首次急性缺血性脑卒中患者199例。依据血尿酸水平将患者分为4组[≤280 μmol/L组(n=50)、280.1~331 μmol/L组(n=50)、331.1~398 μmol/L组(n=50)和>398 μmol/L组(n=49)],分析各组血尿酸与TOAST分型等指标的相关性。采用改良Rankin量表评价患者发病3个月后的预后情况,0~2分为预后良好组(n=157),3~6分为预后不良组(n=42),比较两组预后与血尿酸等指标的相关性。结果不同血尿酸组TOAST分型差异无统计学意义(P>0.05),性别、血脂异常占比和血同型半胱氨酸水平差异均有统计学意义(P<0.05);经有序多分类Logistic回归分析,男性(OR=2.984,95%CI:1.603~5.553,P=0.001)和血脂异常(OR=2.600,95%CI:1.442~4.686,P=0.001)均与高血尿酸水平有关。不同预后组血尿酸水平差异无统计学意义(P>0.05),基线NIHSS评分和基线Barthel指数差异有统计学意义(P<0.01),经二元Logistic回归分析,较低基线Barthel指数是患者预后不良的危险因素(OR=0.905,95%CI:0.867~0.944,P=0.000)。结论血尿酸与首次急性缺血性脑卒中患者TOAST分型和预后未显示出相关性,但是男性和血脂异常均与高血尿酸有关,且较低基线Barthel指数提示预后不良。

关键词: 缺血性卒中, 血尿酸, TOAST分型, 预后

Abstract:

Objective To explore the correlation between serum uric acid (SUA) levels with the Trial of Org 10172 in Acute Stroke Treatment (TOAST) classification and long-term prognosis in patients with first-onset acute ischemic stroke (AIS). Methods A total of 199 patients with first-onset AIS who were hospitalized at Zhuhai People's Hospital from October 2020 to October 2021 were enrolled. They were divided into 4 groups based on SUA levels, which consisted of ≤280 μmol/L group (n=50), 280.1-331 μmol/L group (n=50), 331.1-398 μmol/L group (n=50) and >398 μmol/L group (n=49), and the correlation between SUA levels and TOAST classification was analyzed. The modified Rankin scale was used to evaluate the prognosis of patients after 3 months of onset, and the patients were assigned into good prognosis group (modified Rankin scale: 0-2 points, n=157) and poor prognosis group (modified Rankin scale: 3-6 points, n=42). The correlation between SUA levels and the prognosis of the two groups was compared. Results There was no statistically significant difference in TOAST classification among different SUA groups (P>0.05), but there were overall statistically significant differences in gender, proportion of dyslipidemia, and blood homocysteine levels (P<0.05). The ordinal multinomial logistic regression analysis indicated both male (OR=2.984, 95%CI: 1.603-5.553, P=0.001) and dyslipidemia (OR=2.600, 95%CI: 1.442-4.686, P=0.001) were associated with high SUA levels. There was no statistically significant difference in SUA levels between good prognosis group and poor prognosis group (P>0.05), but there was a statistically significant difference in baseline scores of National Institute of Health Stroke Scale (NIHSS) and Barthel Index (BI)(P<0.01). Binary logistic regression analysis showed a lower baseline score of BI was a risk factor for poor prognosis in the patients (OR=0.905, 95%CI: 0.867-0.944, P=0.000). Conclusion There was no correlation between SUA levels with TOAST classification and prognosis in patients with first-onset AIS, but both male and dyslipidemia were associated with high SUA levels, and a lower baseline score of BI indicated poor prognosis.

Key words: ischemic stroke, serum uric acid, TOAST classification, prognosis

中图分类号:

R743.3

宋梦姣, 王睿琪, 曹灿, 程光森, 刘羽, 李忠亮, 杨建豪. 血尿酸与首次急性缺血性脑卒中患者TOAST分型及预后的相关性[J]. 临床荟萃, 2024, 39(3): 216-221.

Song Mengjiao, Wang Ruiqi, Cao Can, Cheng Guangsen, Liu Yu, Li Zhongliang, Yang Jianhao. Correlation between serum uric acid with TOAST classification and prognosis in patients with first-onset acute ischemic stroke[J]. Clinical Focus, 2024, 39(3): 216-221.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.03.003

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I3/216

图/表 4

参考文献 29

[1]	中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国急性缺血性脑卒中诊治指南2018[J]. 中华神经科杂志, 2018, 51(9):666-682.
[2]	中华医学会神经病学分会,中华医学会神经病学分会脑血管病学组. 中国缺血性卒中和短暂性脑缺血发作二级预防指南2022[J]. 中华神经科杂志, 2022, 55(10):1071-1110.
[3]	Padda J, Khalid K, Padda S, et al. Hyperuricemia and its association with ischemic stroke[J]. Cureus, 2021, 13(9):e18172.
[4]	McArdle PF, Kittner SJ, Ay H, et al. Agreement between TOAST and CCS ischemic stroke classification: The NINDS SiGN study[J]. Neurology, 2014, 83(18):1653-1660. doi: 10.1212/WNL.0000000000000942 pmid: 25261504
[5]	Li L, Zhang Y, Zeng C. Update on the epidemiology, genetics, and therapeutic options of hyperuricemia[J]. Am J Transl Res, 2020, 12(7):3167-3181. pmid: 32774692
[6]	中国民族卫生协会重症代谢疾病分会,高尿酸血症相关疾病诊疗多学科共识专家组. 中国高尿酸血症相关疾病诊疗多学科专家共识(2023年版)[J]. 中国实用内科杂志, 2023, 43(6):461-480.
[7]	Irfan M, Jawaid W, Hashmat O, et al. Association between hyperuricemia and acute ischemic stroke in patients at a tertiary care hospital[J]. Cureus, 2020, 12(10):e10899.
[8]	Wang YF, Li JX, Sun XS, et al. High serum uric acid levels are a protective factor against unfavourable neurological functional outcome in patients with ischaemic stroke[J]. J Int Med Res, 2018, 46(5):1826-1838.
[9]	Kang DH, Ha SK. Uric acid puzzle: Dual role as anti-oxidantand pro-oxidant[J]. Electrolyte Blood Press, 2014, 12(1):1-6.
[10]	Lima WG, Martins-Santos ME, Chaves VE. Uric acid as a modulator of glucose and lipid metabolism[J]. Biochimie, 2015, 116:17-23. doi: 10.1016/j.biochi.2015.06.025 pmid: 26133655
[11]	Qiao T, Wu H, Peng W. The relationship between elevated serum uric acid and risk of stroke in adult: An updated and dose-response meta-analysis[J]. Front Neurol, 2021, 12:674398.
[12]	Dong Y, Shi H, Chen X, et al. Serum uric acid and risk of stroke: A dose-response meta-analysis[J]. J Clin Biochem Nutr, 2021, 68(3):221-227. doi: 10.3164/jcbn.20-94 pmid: 34025024
[13]	Zhang S, Liu L, Huang YQ, et al. The association between serum uric acid levels and ischemic stroke in essential hypertension patients[J]. Postgrad Med, 2020, 132(6):551-558.
[14]	Borghi C, Domienik-Karłowicz J, Tykarski A, et al. Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update[J]. Cardiol J, 2021, 28(1):1-14. doi: 10.5603/CJ.a2021.0001 pmid: 33438180
[15]	郭泽铭. 血清尿酸水平与缺血性脑卒中TOAST分型的关系研究[D]. 福州: 福建医科大学, 2015.
[16]	王少华. 血尿酸与急性缺血性脑卒中TOAST分型及早期预后的相关性研究[D]. 南宁: 广西中西药大学, 2015.
[17]	窦月颖. 中年人血尿酸与急性缺血性卒中的相关性分析[D]. 邯郸: 河北工程大学, 2019.
[18]	Lei Z, Cai J, Hong H, et al. Serum uric acid level and outcome of patients with ischemic stroke: A systematic review and meta-analysis[J]. Neurologist, 2019, 24(4):121-131. doi: 10.1097/NRL.0000000000000234 pmid: 31246721
[19]	Wang Z, Lin Y, Liu Y, et al. Serum uric acid levels and outcomes after acute ischemic stroke[J]. Mol Neurobiol, 2016, 53(3):1753-1759. doi: 10.1007/s12035-015-9134-1 pmid: 25744569
[20]	Sun Z, Feng J, He M, et al. Higher uric acid is associated with better discharge recovery and short-term outcome in stroke patients treated with thrombolysis[J]. Neurol Sci, 2021, 42(8):3225-3231. doi: 10.1007/s10072-020-04919-z pmid: 33241534
[21]	Mangal AC, Guria RT, Singh MK. Serum uric acid level in acute ischaemic stroke[J]. J Evol Med Dent Sci, 2013, 2(36):6915-6926.
[22]	Karagiannis A, Mikhailidis DP, Tziomalos K, et al. Serum uric acid as an independent predictor of early death after acute stroke[J]. Circ J, 2007, 71(7):1120-1127. doi: 10.1253/circj.71.1120 pmid: 17587721
[23]	Cabrera Naranjo FH, Saavedra Santana P, González Hernández A, et al. Hyperuricaemia as a prognostic factor for acute ischaemic stroke[J]. Neurologia (Engl Ed), 2021, 36(4):279-284. doi: 10.1016/j.nrl.2018.01.012 pmid: 29526317
[24]	Bc PK, Somannavar VG. A study on the role of serum calcium, serum albumin and serum uric acid as markers of initial neurological severity and short term outcome indicators in acute ischemic stroke[J]. J Assoc Physicians India, 2022, 70(4):11-12. pmid: 35443422
[25]	Chauhan H, Atam V, Sawlani KK, et al. Role of serum homocysteine, C-reactive protein (CRP), uric acid & pro-brain natriuretic peptide (Pro-BNP) in predicting the functional outcome in patients with ischemic stroke-a prospective observational study from North India[J]. J Assoc Physicians India, 2022, 70(4):11-12.
[26]	Zhang M, Wang Y, Wang K, et al. Association between uric acid and the prognosis of acute ischemic stroke: A systematic review and meta-analysis[J]. Nutr Metab Cardiovasc Dis, 2021, 31(11):3016-3023. doi: 10.1016/j.numecd.2021.07.031 pmid: 34625360
[27]	Abdul-Rahim AH, Fulton RL, Sucharew H, et al. National institutes of health stroke scale item profiles as predictor of patient outcome: External validation on safe implementation of thrombolysis in stroke-monitoring study data[J]. Stroke, 2015, 46(10): 2779-2785. doi: 10.1161/STROKEAHA.115.010380 pmid: 26359360
[28]	Tan BY, Wan-Yee K, Paliwal P, et al. Good intracranial collaterals trump poor ASPECTS (alberta stroke program early CT score) for intravenous thrombolysis in anterior circulation acute ischemic stroke[J]. Stroke, 2016, 47(9):2292-2298. doi: 10.1161/STROKEAHA.116.013879 pmid: 27491731
[29]	李朝. 急性脑梗死患者hs-CRP与rt-PA溶栓预后的相关性分析[D]. 邯郸: 河北工程大学, 2020.

项目	SUA(μmol/L)				H/χ²值	P值
项目	≤280(n=50)	280.1~331(n=50)	331.1~398(n=50)	>398(n=49)	H/χ²值	P值
年龄(岁)	61.00(54.50, 66.25)	60.00(52.00, 70.00)	61.00(52.75, 66.00)	57.00(49.00, 65.50)	1.754	0.625
性别[例(%)]
男女	32.00(64.00)^* 18.00(36.00)^*	32.00(64.00)^* 18.00(36.00)^*	41.00(82.00) 9.00(18.00)	46.00(93.88) 3.00(6.12)	17.406	0.001^a
吸烟[例(%)]	17.00(34.00)	21.00(42.00)	24.00(48.00)	25.00(51.02)	3.414	0.332^a
饮酒[例(%)]	12.00(24.00)	17.00(34.00)	20.00(40.00)	19.00(38.78)	3.517	0.319^a
高血压[例(%)]	35.00(70.00)	36.00(72.00)	30.00(60.00)	39.00(79.59)	4.643	0.200^a
糖尿病[例(%)]	15.00(30.00)	15.00(30.00)	13.00(26.00)	11.00(22.45)	0.992	0.803^a
血脂异常[例(%)]	30.00(60.00)^*	35.00(70.00)	39.00(78.00)	43.00(87.76)	10.707	0.013^a
血同型半胱氨酸(μmol/L)	12.03(10.50, 15.11)^*	13.85(11.70, 16.73)	15.95(13.63, 18.01)^#	15.90(13.71, 18.28)	25.110	0.000
基线NIHSS评分(分)	2.00(1.00, 5.00)	2.00(1.00, 3.00)	2.00(1.00, 3.00)	3.00(1.00, 4.00)	3.359	0.339
基线Barthel指数	85.00(60.00, 95.00)	90.00(78.75, 96.25)	87.50(70.00, 100.00)	80.00(65.00, 95.00)	4.615	0.202
TOAST分型[例(%)]
大动脉粥样硬化型	26.00(52.00)	31.00(62.00)	30.00(60.00)	25.00(51.02)
小动脉闭塞型	22.00(44.00)	16.00(32.00)	19.00(38.00)	21.00(42.86)
心源性栓塞型	1.00(2.00)	3.00(6.00)	0	1.00(2.04)	-	0.605^b
其他明确病因型	1.00(2.00)	0	1.00(2.00)	2.00(4.08)
不明原因型	0	0	0	0

项目	SUA(μmol/L)				H/χ²值	P值
项目	≤280(n=50)	280.1~331(n=50)	331.1~398(n=50)	>398(n=49)	H/χ²值	P值
年龄(岁)	61.00(54.50, 66.25)	60.00(52.00, 70.00)	61.00(52.75, 66.00)	57.00(49.00, 65.50)	1.754	0.625
性别[例(%)]
男女	32.00(64.00)^* 18.00(36.00)^*	32.00(64.00)^* 18.00(36.00)^*	41.00(82.00) 9.00(18.00)	46.00(93.88) 3.00(6.12)	17.406	0.001^a
吸烟[例(%)]	17.00(34.00)	21.00(42.00)	24.00(48.00)	25.00(51.02)	3.414	0.332^a
饮酒[例(%)]	12.00(24.00)	17.00(34.00)	20.00(40.00)	19.00(38.78)	3.517	0.319^a
高血压[例(%)]	35.00(70.00)	36.00(72.00)	30.00(60.00)	39.00(79.59)	4.643	0.200^a
糖尿病[例(%)]	15.00(30.00)	15.00(30.00)	13.00(26.00)	11.00(22.45)	0.992	0.803^a
血脂异常[例(%)]	30.00(60.00)^*	35.00(70.00)	39.00(78.00)	43.00(87.76)	10.707	0.013^a
血同型半胱氨酸(μmol/L)	12.03(10.50, 15.11)^*	13.85(11.70, 16.73)	15.95(13.63, 18.01)^#	15.90(13.71, 18.28)	25.110	0.000
基线NIHSS评分(分)	2.00(1.00, 5.00)	2.00(1.00, 3.00)	2.00(1.00, 3.00)	3.00(1.00, 4.00)	3.359	0.339
基线Barthel指数	85.00(60.00, 95.00)	90.00(78.75, 96.25)	87.50(70.00, 100.00)	80.00(65.00, 95.00)	4.615	0.202
TOAST分型[例(%)]
大动脉粥样硬化型	26.00(52.00)	31.00(62.00)	30.00(60.00)	25.00(51.02)
小动脉闭塞型	22.00(44.00)	16.00(32.00)	19.00(38.00)	21.00(42.86)
心源性栓塞型	1.00(2.00)	3.00(6.00)	0	1.00(2.04)	-	0.605^b
其他明确病因型	1.00(2.00)	0	1.00(2.00)	2.00(4.08)
不明原因型	0	0	0	0

因素	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
因素	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
性别(女性组为对照)	1.093	0.317	11.902	0.001	2.984	1.603	5.553
血脂异常(血脂正常组为对照)	0.955	0.301	10.103	0.001	2.600	1.442	4.686
血同型半胱氨酸	0.012	0.010	1.570	0.210	1.012	0.993	1.031

因素	回归系数	标准误	Wald χ²值	P值	OR值	95%CI
因素	回归系数	标准误	Wald χ²值	P值	OR值	下限	上限
性别(女性组为对照)	1.093	0.317	11.902	0.001	2.984	1.603	5.553
血脂异常(血脂正常组为对照)	0.955	0.301	10.103	0.001	2.600	1.442	4.686
血同型半胱氨酸	0.012	0.010	1.570	0.210	1.012	0.993	1.031

项目	预后良好组(n=157)	预后不良组(n=42)	Z/χ²值	P值
年龄(岁)	60.00(52.00, 66.00)	60.00(51.75, 69.25)	0.587	0.557
性别[例(%)]
男女	120.00(76.43) 37.00(23.57)	31.00(73.81) 11.00(26.19)	0.125	0.724^a
吸烟[例(%)]	69.00(43.95)	18.00(42.86)	0.016	0.899^a
饮酒[例(%)]	53.00(33.76)	15.00(35.71)	0.056	0.812^a
高血压[例(%)]	112.00(71.34)	28.00(66.67)	0.347	0.556^a
糖尿病[例(%)]	41.00(26.11)	13.00(30.95)	0.392	0.531^a
血脂异常[例(%)]	116.00(73.89)	31.00(73.81)	0.000	0.992^a
血同型半胱氨酸(μmol/L)	14.41(12.00, 17.59)	14.81(11.78, 17.87)	0.321	0.748
基线NIHSS评分(分)	2.00(1.00, 3.00)	5.00(3.00, 8.00)	7.521	0.000
基线Barthel指数	90.00(80.00, 100.00)	60.00(45.00, 65.00)	-8.176	0.000
SUA( μmol/L)	324.00(278.50, 392.00)	351.50(289.50, 421.75)	1.071	0.284
SUA[例(%)]
≤280 μmol/L	41.00(26.11)	9.00(21.43)
280.1~331 μmol/L	42.00(26.75)	8.00(19.05)	2.190	0.534^a
331.1~398 μmol/L	38.00(24.20)	12.00(28.57)
>398 μmol/L	36.00(22.93)	13.00(30.95)
TOAST分型[例(%)]
大动脉粥样硬化型	86.00(54.78)	26.00(61.90)
小动脉闭塞型	64.00(40.76)	14.00(33.33)
心源性栓塞型	4.00(2.55)	1.00(2.38)	-	0.789^b
其他明确病因型	3.00(1.91)	1.00(2.38)
不明原因型	0	0
静脉溶栓[例(%)]	16.00(10.19)	8.00(19.05)	0.245	0.117^a
血管内介入治疗[例(%)]	20.00(12.74)	6.00(14.29)	0.070	0.792^a

血尿酸与首次急性缺血性脑卒中患者TOAST分型及预后的相关性

Correlation between serum uric acid with TOAST classification and prognosis in patients with first-onset acute ischemic stroke

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

图/表 4

参考文献 29

相关文章 15

编辑推荐

Metrics

本文评价

[1]	赵旭辉, 黄小敏, 达德转, 许焱, 崔晓东, 李红玲. 基于生物信息学筛选影响胃癌患者预后的糖酵解相关基因[J]. 临床荟萃, 2024, 39(1): 20-29.
[2]	刘丽丽, 袁宇婷, 赖耿良, 田川, 蓝翔, 叶中绿. 儿童急性淋巴细胞白血病第15天微小残留与预后的关系[J]. 临床荟萃, 2024, 39(1): 47-52.
[3]	崔兰丹, 杨春燕. 脓毒症患者甲状腺激素的变化特点及研究进展[J]. 临床荟萃, 2024, 39(1): 70-74.
[4]	王涛, 高玉伟, 王兴华, 胡秀红, 崔红蕊, 徐保振, 杨洪娟. 抗磷脂酶A2受体抗体与特发性膜性肾病的相关性[J]. 临床荟萃, 2023, 38(7): 606-612.
[5]	辛燕红, 郎桂艳, 陈子为, 王东玉. 中性粒细胞-淋巴细胞比值和血小板-淋巴细胞比值预测急性轻型缺血性脑卒中患者认知障碍的价值[J]. 临床荟萃, 2023, 38(6): 504-509.
[6]	高秦宇, 包蓓艳, 金燕, 赵宇. IgA肾病合并抑郁状态患者的临床特征和预后影响因素分析[J]. 临床荟萃, 2023, 38(6): 510-515.
[7]	孙星星, 林海. 儿童重症肺炎的免疫功能变化及预后危险因素[J]. 临床荟萃, 2023, 38(6): 521-525.
[8]	贺翔渝, 潘燕, 张小林. 血清脂蛋白相关磷脂酶A2水平与急性缺血性脑卒中病情及预后的关系[J]. 临床荟萃, 2023, 38(4): 315-318.
[9]	杨金强, 张仁敏. 降钙素原与血小板比值评估发热伴血小板减少综合征预后的价值[J]. 临床荟萃, 2023, 38(4): 346-351.
[10]	贾阳娟, 韩凝, 郭慧, 李岩鹏, 李灿灿, 李建国. MMSE和MoCA对卒中后轻度血管性认知障碍早期筛查的价值[J]. 临床荟萃, 2023, 38(3): 221-226.
[11]	姚美芬, 丁刚玉, 徐建华, 王国江. 重组组织型纤溶酶原激活剂治疗急性轻型缺血性脑卒中的有效性和安全性[J]. 临床荟萃, 2023, 38(3): 227-231.
[12]	刘彬, 翟桂兰, 孙巨峰. 中性粒细胞计数联合血尿酸对急性一氧化碳中毒患者心肌损伤的预测价值[J]. 临床荟萃, 2023, 38(3): 245-249.
[13]	张娜, 孙越, 董晗, 赵鹏, 杨昕, 祁源, 王玲玲. SPARC表达水平与非小细胞肺癌患者预后关系的meta分析[J]. 临床荟萃, 2023, 38(11): 972-978.
[14]	罗伟刚, 徐玉珠, 张玲雁, 武湘云, 步玮, 任慧玲. 血小板功能分析仪PFA-200 P2Y对氯吡格雷用于急性缺血性卒中二级预防的预测价值[J]. 临床荟萃, 2023, 38(11): 979-983.
[15]	白碧玥, 彭艳, 朱晓峰, 尹昌浩. 缺血性脑卒中影响侧支循环建立因素的研究进展[J]. 临床荟萃, 2023, 38(11): 1034-1037.

因素	回归系数	标准误	Waldχ²值	P值	OR值	95%CI
因素	回归系数	标准误	Waldχ²值	P值	OR值	下限	上限
基线NIHSS评分	-0.032	0.131	0.059	0.808	0.969	0.749	1.252
基线Barthel指数	-0.100	0.022	21.332	0.000	0.905	0.867	0.944

因素	回归系数	标准误	Waldχ²值	P值	OR值	95%CI
因素	回归系数	标准误	Waldχ²值	P值	OR值	下限	上限
基线NIHSS评分	-0.032	0.131	0.059	0.808	0.969	0.749	1.252
基线Barthel指数	-0.100	0.022	21.332	0.000	0.905	0.867	0.944